Iveena Delivery Systems Inc. has been awarded a $2 million phase II Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance the development of novel topical eye drops to control pediatric myopia and other refractive disorders.

A novel mRNA drug, 3’UTRMYC1-18 (UTRxM1-18), has demonstrated notable efficacy in preclinical models of aggressive pancreatic cancer, addressing a disease that is often resistant to conventional treatments.

Atai Life Sciences NV has been awarded a multiyear, milestone-driven grant worth up to $11.4 million by the National Institute on Drug Abuse (NIDA) to support development of Atai’s novel 5-HT2A/2C receptor agonists with nonhallucinogenic potential for opioid use disorder.

Vectory Therapeutics BV and Shape Therapeutics Inc. have entered into an option and license agreement granting Vectory an exclusive option to evaluate Shape’s deep brain penetrating AAV capsid, SHP-DB1, for vectorized antibody payloads against three therapeutic targets.

Although the development pipeline for obesity treatments is expanding rapidly, weight loss is often accompanied by a concurrent reduction in lean muscle mass, highlighting the need for novel therapeutic approaches that promote fat loss while preserving muscle. Activin type II receptors (ACTRIIA/B) are regulators of muscle homeostasis, while the glucose-dependent insulinotropic polypeptide receptor (GIPR) plays a role in energy balance and adiposity.